Medtronic, Inc. (NYSE: MDT), today announced the imminent release of the pivotal U.S. data on its Resolute� drug-eluting stent (DES) at ACC.11, the 60th Annual Scientific Session & Expo of the American College of Cardiology, which takes place April 2-5 in New Orleans. The one-year results of the study, called RESOLUTE US, will be presented in the late-breaking clinical trials session for interventional cardiology on Monday, April 4. These new data complete Medtronic's submission to the U.S...
No comments:
Post a Comment